Trial · NCT00929162

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

NCT00929162, Phase 2, Terminated, AstraZeneca; results first posted 2012-06-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer. Trials, record NCT00929162. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00929162

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
NCT number: NCT00929162
Status: Terminated
Phases: Phase 2
Enrollment: 120 participants, actual
Lead sponsor: AstraZeneca
Conditions: Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Interventions: ZD4054 Zibotentan, Paclitaxel, Carboplatin, Placebo
First posted: 2009-06-26
Last updated: 2012-08-07
Results first posted: 2012-06-06

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival	Patients were followed for progression up to 2 years	Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method.
Secondary	Overall Survival	Patients were followed for survival up to 2 years	Median time (in months) from randomisation until death using the Kaplan-Meier method.
Secondary	Tumour Response Rate	While receiving paclitaxel + carboplatin study visits were aliged with its administration ie every 3 weeks, then every 6 weeks (up to 2 years)	Objective response rate defined as participants with a complete or partial response according to RECIST

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival	Patients were followed for progression up to 2 years		Months	MEDIAN
SECONDARY	Overall Survival	Patients were followed for survival up to 2 years	Overall Survival was not analysed as the study was terminated early.
SECONDARY	Tumour Response Rate	While receiving paclitaxel + carboplatin study visits were aliged with its administration ie every 3 weeks, then every 6 weeks (up to 2 years)	The number of participants for analysis corresponds to patients with measurable disease at study entry	Participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression Free Survival	ZD4054+Paclitaxel+Carboplatin	7.6	Inter-Quartile Range 6.6 to 10.2	Months
Progression Free Survival	Placebo+Paclitaxel+Carboplatin	10.0	Inter-Quartile Range 7.1 to 12.2	Months
Tumour Response Rate	ZD4054+Paclitaxel+Carboplatin	21		Participants
Tumour Response Rate	Placebo+Paclitaxel+Carboplatin	34		Participants

Source ClinicalTrials.gov

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	ZD4054+Paclitaxel+Carboplatin	59
Overall Study	STARTED	Placebo+Paclitaxel+Carboplatin	61
Overall Study	Patients Who Received Treatment	ZD4054+Paclitaxel+Carboplatin	58
Overall Study	Patients Who Received Treatment	Placebo+Paclitaxel+Carboplatin	58
Overall Study	COMPLETED	ZD4054+Paclitaxel+Carboplatin	11
Overall Study	COMPLETED	Placebo+Paclitaxel+Carboplatin	19
Overall Study	NOT COMPLETED	ZD4054+Paclitaxel+Carboplatin	48
Overall Study	NOT COMPLETED	Placebo+Paclitaxel+Carboplatin	42

Source ClinicalTrials.gov

Adverse events156

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	ZD4054+Paclitaxel+Carboplatin	30	58
other	Anaemia	Blood and lymphatic system disorders	Placebo+Paclitaxel+Carboplatin	25	58
other	Neutropenia	Blood and lymphatic system disorders	ZD4054+Paclitaxel+Carboplatin	26	58
other	Neutropenia	Blood and lymphatic system disorders	Placebo+Paclitaxel+Carboplatin	22	58
other	Leukopenia	Blood and lymphatic system disorders	ZD4054+Paclitaxel+Carboplatin	20	58
other	Leukopenia	Blood and lymphatic system disorders	Placebo+Paclitaxel+Carboplatin	15	58
other	Thrombocytopenia	Blood and lymphatic system disorders	ZD4054+Paclitaxel+Carboplatin	11	58
other	Thrombocytopenia	Blood and lymphatic system disorders	Placebo+Paclitaxel+Carboplatin	11	58
other	Vertigo	Ear and labyrinth disorders	ZD4054+Paclitaxel+Carboplatin	2	58
other	Vertigo	Ear and labyrinth disorders	Placebo+Paclitaxel+Carboplatin	4	58

1 to 10 of 156Source ClinicalTrials.gov

See all 156 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	ZD4054+Paclitaxel+Carboplatin
Total, all-cause mortality	Placebo+Paclitaxel+Carboplatin
Total, other adverse events	ZD4054+Paclitaxel+Carboplatin	57	58
Total, other adverse events	Placebo+Paclitaxel+Carboplatin	58	58
Total, serious adverse events	ZD4054+Paclitaxel+Carboplatin	19	58
Total, serious adverse events	Placebo+Paclitaxel+Carboplatin	13	58

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23234805	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
ZD4054+Paclitaxel+Carboplatin vs Placebo+Paclitaxel+Carboplatin: Tumour Response Rate	Trial comparisons
ZD4054+Paclitaxel+Carboplatin vs Placebo+Paclitaxel+Carboplatin: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00929162

GET https://conductscience.org/api/trials/v1/NCT00929162/events?page=2

API reference For AI assistants